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Upon completion of this article, the reader should be able to: 1) Identify the potential reasons of increased energy expenditure in children with CP; 2) Discuss the association of gait analysis and energy expenditure measurements in children with and without CP; and 3) Identify the different methodologic approaches used to evaluate energy expenditure in children with CP.
Cerebral palsy (CP) is the most common cause of physical disability in children, with an incidence of 1.5 to 3 per 1000 live births. 1 CP encompasses a group of permanent developmental disorders of movement and posture that result in limitation of activity, which are attributed to nonprogressive disturbances that occur in the developing fetal or infant brain. 2, 3 Spasticity is a prevalent disabling clinical symptom in children with CP, along with a velocitydependent increase in muscle resistance against passive lengthening, especially in the gastrocnemius muscle (GCM). Botulinum toxin A (BTX-A) has emerged during the last two decades as a treatment for spasticity. BTX-A inhibits the release of acetylcholine in the neuromuscular junction, which causes partial chemodenervation in the injected muscle. 4 Since the therapeutic use of BTX-A for CP was first reported by Koman et al., 5 most subsequent studies have reported that BTX-A injection has a positive effect on ambulation in children with CP; however, these results should be critically analyzed because of the modest methodologic quality of the research. 6 A systematic review by Baird and Vargus-Adams, 7 which examined the variety of outcome measures used in such research since the publication of the International Classification of Functioning, reported that clinical outcomes were focused on spasticity and range of motion, rather than on International Classification of Functioning activity and participation domains, including walking. As such, three-dimensional (3D) gait analysis was reported to be an objective and reliable tool for the evaluation of functional outcome. 8, 9 Many researchers reported that there is an increase in energy expenditure during walking in children with CP. 3,10Y12 Mechanical inefficiency during ambulation caused by loss of selective motor control, impaired balance, abnormal tone, weakness, and reduced of range of motion contributes to the observed increase in energy expenditure. 10 Although energy assessment has proved to be an effective tool for the evaluation of abnormal gait and orthotic management, measurement of energy expenditure as a routine component of the clinical assessment of BTX-A treatment in children with CP is rare. 3, 13, 14 After BTX-A injection, children with CP may have improved posture and gait; however, there are no sufficient data on the energy they required: increasing or decreasing.
We think that functional gain is the hallmark of treatment in CP. As such, the present study aimed to evaluate the effectiveness of BTX-A treatment on energy expenditure in children with CP and to determine if energy expenditure measurement could be considered a useful tool for evaluating the effectiveness of BTX-A treatment for CP.
MATERIALS AND METHODS
The study included 16 ambulatory pediatric CP patients (10 with hemiplegia and 6 with diplegia) and 13 age-matched healthy controls recruited from our gait laboratory. Inclusion criteria for children with CP included a diagnosis of hemiplegic or diplegic spastic CP, the ability to walk independently without aid, equinus gait, no joint or bone deformities, negative history of orthopedic surgery and casting of the gastrosoleus muscle, indication of BTX-A neurolysis, no use of BTX-A or phenol neurolysis during the previous 6 mos, and physical therapy twice a week. Exclusion criteria were other forms of CP, musculoskeletal contractures greater than 15 degrees, and use of BTX-A within the previous 6 mos. The Institutional Ethics Committee approved the study protocol, and the parents of the children with CP were informed about BXT-A and its mechanism of action and associated complications. Informed consent was provided by the participants' parents/guardians. In all, 16 children (13 boys and 3 girls; mean T SD age, 11.12 T 1.66 yrs) received onabotulinum toxin A (BTX-A) (Botox, Allergan) injections of 3.0 to 6.0 U kg j1 diluted with 100 U 2 ml j1 of 0.09% saline for each muscle. Doses were individualized on the basis of body weight, severity of spasticity, and movement pattern. The degree of spasticity was determined according to the modified Ashworth scale. 15 To facilitate data analysis, modified Ashworth scale scores were adjusted to provide a score range from 0 to 5 (1+ became 2, 2 became 3, and so on). Although the modified Ashworth scale is easy to administer and is commonly used in clinical practice, several studies have reported that the modified Ashworth scale has low-level reliability in children with spastic CP. 16, 17 Local anesthetic (lidocaine cream) was topically applied at the injection site 1 hr before BTX-A injection. The accuracy of manual needle placement was reported to be acceptable for GCM injection in children with CP. 18, 19 Thus, in the present study, the location of injection points was determined according to anatomical landmarks and palpation. Needle positioning was verified via flexing/extending both knee and ankle joints. BTX-A was injected into the GCM at 5 points (3 points on the medial and 2 points on the lateral head). In total, 60% of the BXT-A was injected into the medial GCM and 40% was injected into the lateral GCM. All children in the group with CP underwent 3D gait analysis and energy expenditure measurement 1 to 3 days before injection and 8 wks after injection. Analysis of 3D gait data was performed to examine the interconnectivity of gait data and metabolic data. Use of ankle-foot orthoses was unchanged during the study. Activity measurement in the control group was performed in our gait laboratory.
Gait Measurement
Gait was assessed using a 3D, seven-camera VICON 512 motion measurement system (Oxford Metrics Ltd., Oxford, UK). VICON Clinical Manager software was used for calculating and plotting data. The data collection space was calibrated using a calibration frame and standard calibration procedures before data collection. Then, each child's gait was analyzed under barefoot conditions. In all, 15 reflective markers were placed bilaterally on specific anatomic landmarks on the pelvis, thighs, shanks, and feet, according to the marker protocol of Davis et al. 20 Anthropometric measures of height, weight, leg length, and ankle and knee width were obtained for appropriate anthropometric scaling. Each participant was instructed to walk at a self-selected speed along a walkway containing two force plates embedded in the floor. Video was simultaneously recorded from the back, front, and side. Each child walked on the walkway until three clean trials were obtained. The following kinematic parameters were used to determine the effect of the BTX-A treatment on gait: ankle dorsiflexion at initial contact, ankle dorsiflexion at mid-stance, maximum ankle dorsiflexion in the stance phase, maximum ankle dorsiflexion in the swing phase, and maximum knee extension at mid-stance. Knee recurvatum at midstance and absence of second ankle rocker due to gastrosoleus spasticity or limited knee extension due to hamstring spasticity in the stance phase are the most common gait pathologies seen together with equinus in children with CP. Thus, in addition to ankle kinematics, we also included the knee extension values in the stance phase in our data analysis.
Energy Expenditure
Measurement of walking energy expenditure was performed via the breath-by-breath method, using an open-circuit indirect calorimeter (Vmax 29c, Sensormedics) in both groups. After receiving instruction, each child practiced using the mask and treadmill before data acquisition. After an adequate rest period with the facemask, measurements were obtained during 5 mins of treadmill walking at a speed of 0.5 m sec j1 . It is known that after 2 mins of submaximal walking, children with CP can attain a steady state condition. 3, 21 Aerobic demand (oxygen consumption per unit time) was determined from an expired air sample collected during the www.ajpmr.com final 2 mins of each 5-min walk. Gait analysis and energy expenditure measurement were performed the same day with a sufficient period of rest between measurements. Energy expenditure was measured in our performance laboratory before 3D gait analysis. Participants walked at their self-selected speed during 3D gait analysis, whereas treadmill-selected speed was used during walking energy expenditure measurement.
Statistical Analysis
SPSS version 16.0 for Windows was used for statistical analysis. The Mann-Whitney U test was used to compare differences between the CP and control groups. Repeated group with CP measurements before and after treatment were analyzed using the Wilcoxon U test, pairing each CP patient with his/her own pretreatment result. The level of statistical significance was set at P G 0.05.
RESULTS
There were not any significant differences in mean age, height, or weight between the CP and control groups ( Table 1 ). None of the CP patients reported adverse events or complications associated with BTX-A injection. We measured muscle tonus and temporospatial gait parameters; tonus and cadence both showed statistically significant improvements in the group with CP after treatment ( Table 2) . Table 3 shows mean oxygen consumption per unit time before and after treatment in the group with CP and in the control group. Oxygen consumption in the control group was significantly lower than that in the group with CP at baseline. After BTX-A treatment, oxygen consumption in the group with CP decreased significantly (P G 0.001) and did not differ from that in the control group (P = 0.619).
Energy Expenditure

Kinematics
Kinematic parameter values are shown in Table 3 . Baseline ankle dorsiflexion at initial contact and mid-stance and maximum ankle dorsiflexion in the stance phase and swing phase of the gait cycle in the control group were significantly better than those in the group with CP; however, after BTX-A treatment, there was no significant difference in ankle dorsiflexion at initial contact between the two groups (P = 0.288). Other parameters in the group with CP also improved significantly after treatment.
On the other hand, knee extension angle in the group with CP both before and after treatment was similar to that in the control group (P 9 0.05) ( Table 4 ).
DISCUSSION
Gait analysis and energy expenditure measurement are objective methods of evaluating a child's walking pattern after treatment. If the energy required for walking is greater or unchanged after treatment, the effectiveness of the intervention used should be questioned. 22 The effects of botulinum toxin on the human body's structure and function have been established, although additional research on its clinical effects on International Classification of Functioning activity and participation domains is needed. 7 As such, the present study aimed to determine the effects of BTX-A treatment on gait pathology and energy expenditure in children with CP. Both energy expenditure and gait in the group with CP significantly improved after BTX-A treatment. In fact, posttreatment oxygen consumption and the ankle dorsiflexion angle at initial contact in the group with CP were similar to those in the control group.
Abnormal gait patterns that are the result of increased muscle tone, imbalance between muscle agonists and antagonists across joints, and reduced selective muscle control have been shown to increase energy expenditure in children with CP, as compared with typically developing peers. 23,24 Such gait patterns may limit the ability of affected children to participate in the community. Duffy et al. 25 reported that the rate of oxygen consumption was significantly higher in children with CP than in normal children. 25 Piccinini et al. 24 reported that oxygen consumption did not differ between children with and children without CP but that oxygen cost was higher in children with CP. They also reported that velocity was significantly lower in children with CP and that they exhibited a peculiar walking strategy, not only from a biomechanical point of view but also in energy expenditure; they exhibited reduced velocity while walking to maintain oxygen consumption at a level close to normal. 24 Oxygen cost can be more reliable data in this condition. In the present study, treadmill speed was kept constant during energy expenditure measurement, and oxygen consumption was significantly higher in the group with CP than in the control group.
Recent research reported the interconnectivity between laboratory gait analysis and energy expenditure measurement. 26, 27 The effect of BTX-A treatment on energy expenditure was reported by two randomized placebo-controlled trials. 1, 28 The researchers reported a lack of significant improvement in the physiologic cost index and energy cost index after BTX-A injection. This is in contrast to the present study's observation of a significant difference in the oxygen consumption rate between the CP and control groups. We think that the differences in the studies' findings are a result of differences in the methodologic approaches used to evaluate energy expenditure. Boyd et al. 29 reported that low-technology measures of energy expenditure based on heart rate (e.g., the physiologic cost index) are not suitable as a measure of treatment outcome in children with disabilities. Direct measurement of energy expenditure, such as oxygen cost, are reliable and repeatable, 29 and as such, an approach to energy expenditure measurement was used in the present study. The present results may be more reliable than those previously reported.
The present study's results also show that energy expenditure in the children with CP improved significantly after BTX-A injection into the GCM. Nonetheless, Corry et al. 30 injected BTX-A into the hamstring muscle in children with CP but did not observe a reduction in energy expenditure. The high-technology measurement methodology used in that study was similar to that used in the present study. As such, differences in the method of energy expenditure measurement cannot account for the differences in the results obtained. Corry et al. 30 injected a muscle different from that injected in the present study and reported that BTX-A did not produce significant change in knee kinematics at 12 wks after treatment. In contrast, ankle kinematics improved significantly after treatment in the present study; however, Corry et al. 30 measured metabolic differences at self-selected speed, whereas the present study used a treadmill-selected constant speed. We think that these methodologic differences account for the differences in the studies' findings.
Treadmill-selected speed was used in the present study during energy expenditure measurement to prevent the disadvantage of self-selected speed on metabolic data, because children walking at www.ajpmr.com self-selected speed would prefer a comfortable level that will be similar to baseline walking pattern. On the other hand, children walking at a constant treadmill-selected speed cannot reduce their speed to maintain oxygen consumption at a comfortable level; we think that constant treadmill-selected speed prevents this from happening. Nevertheless, it remains unclear which approach (self-selected or treadmill-selected speed) to measuring metabolic data is more effective.
The present study's results show that there is interconnectivity between laboratory gait analysis and energy expenditure measurement. Many studies have reported improvement in gait characteristics, including temporospatial, kinematic, and kinetic variables, in the ankle joint by using 3D gait analysis after BTX-A injection to the GCM. 31Y33 The present study's results confirm these findings and show that kinematic variables in ankle dorsiflexion in children with CP improved, both in the stance and swing phases of the gait cycle, after BTX-A treatment. The present results also show that BTX-A treatmentY related decrease in spasticity in calf muscles and changes in viscoelastic properties facilitated greater ankle dorsiflexion. 1,31Y38 Proximal joint kinematics during gait, including those of the knee and hip joints, may also affect energy expenditure rates; however, knee extension in the stance phase and knee flexion in the swing phase were similar in the present study's CP and control groups. As such, we think that the kinematics of these joints did not significantly affect the data we data collected. We think that the children in the present study's group with CP maintained a constant walking speed that was safe and energy cost-effective during 3D gait analysis, because faster walking speeds increase joint compression and peak muscle moments.
Kernozek et al. 39 examined the effect of walking speed and cadence on lower limb joint reaction forces and torques in healthy female participants and reported that increased cadence at the preferred gait speed reduced ankle, knee, and hip joint compression forces. Thus, walking speed has a slightly greater effect on reducing joint compression and peak muscle moments than does altering cadence. Rossa and Engsberg 40 reported that strength was correlated with walking, gait speed, and stride length, unlike spasticity in children with diplegic CP. Although in the present study, spasticity was significantly lower in the group with CP after BTX-A treatment, as compared with pretreatment, this improvement alone was not sufficient to increase walking speed. We observed that muscle strength, especially in the ankle dorsiflexor and plantarflexor muscles, might have affected walking speed and should be measured before and after intervention for the prediction of gait speed. Unfortunately, our trial does not have adequate data to reveal this point.
Energy expenditure measurement has been used in a limited number of studies, usually to evaluate the effect of ankle-foot orthoses or walking aids on walking efficiency. 3, 41 To the best of our knowledge, the present study is the first to use energy expenditure measurement to evaluate the effect of BTX-A treatment on equinus gait in children with CP; clearly, additional research with more patients and different walking patterns is required to validate this tool for general use. Moreover, additional research is also needed to clarify the differences between the effects of self-selected and treadmill-selected speed on metabolic data collection, and long-term follow-up is required to assess the persistence of functional gain.
CONCLUSIONS
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